Abstract:
Provided herein are methods for producing cyclic and acyclic ketones from trimerization and dimerization of alkyl ketones, including for example methyl ketones. Such cyclic and acyclic ketones may be suitable for use as fuel and lubricant precursors, and may be hydrodeoxygenated to form their corresponding cycloalkanes and alkanes. Such cycloalkanes and alkanes may be suitable for use as fuels, including jet fuels, and lubricants.
Abstract:
The invention provides a compound of Formula (I), pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
Abstract:
The present invention relates to a novel zeolite and to analogous molecular sieve materials thereof, which are synthesized by adding a specially designed surfactant to a synthetic composition of zeolite, in which mesopores 2-50 nm in size are regularly or irregularly arranged. The mesopores are formed by a crystalline framework having a thickness not greater than 10 single-unit-cells with one or more crystalline axes, and organic combinations thereof. In addition, the present invention provides micro-mesoporous molecular sieve materials activated or functionalized by dealumination, ion exchange or other post treatments, and the use thereof as a catalyst. These novel materials have dramatically increased external surface area and pore volume by virtue of the hierarchical bonding structure of the micropores and mesopores. The result is an increase in molecular diffusion, and therefore it is expected that these novel materials have much higher activities than conventional zeolites in the functions as a catalyst and an ion exchange resin.
Abstract:
Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung von 2-Methyl-3-(4-tert-butylphenyl)-propanal mit hoher para-Isomerenreinheit sowie ein Verfahren zur Herstellung von 4-tert-Butylbenzaldehyd mit hoher para-Isomerenreinheit.
Abstract:
The invention relates to a method for producing aliphatic aldehydes of the general formula (I) by reacting aldehyde of the general formula (II) with an aldehyde of the general formula (III), where R1 is hydrogen or a methyl group, R2 is a straight-chain or branched alkyl radical having 1 to 4 carbon atoms, and the two X are each hydrogen or together are a further C-C bond, in the presence of an aldol condensation catalyst to form the substituted octenal of the general formula (I) and subsequently optionally hydration, either continuously or in batches, to form the corresponding octanal of the formula (I). The invention is characterized in that the aldehydes of the general formula III and II are used in a molar ratio of III:II between 1.4:1 and 0.6:1.
Abstract:
The present invention concerns a process for the preparation of a compound of formula (I) wherein R represents a Me or Et group, as well as said compound in the form of any one of its stereoisomers or mixture thereof. The invention concerns also the use of compound (I) for the synthesis of β-santalol or of derivatives thereof.
Abstract:
The present invention relates to 3-(4-hydroxy-3-methoxyphenyl)-1 -(4- hydroxyphenyl)-1 -propanone of formula (I), a method for preparation of the compound of formula (I) and its use as an antioxidant in formulations and products.
Abstract:
Disclosed are methods for identifying individuals suffering from a CNS disorder (including Alzheimer's Disease, behavioral disorders, and the like) that could be treated with a CNS drug with greater therapeutic efficacy and lower side effects and the compounds useful for such treatment. Also disclosed are methods for predicting the efficacy of a drug candidate for the treatment of a CNS disorder. The technology is also applicable to drug discovery for use in animal models of neurodegenerative diseases.
Abstract:
The invention relates to novel tetralone based amines and their use in the treatment of central nervous system (CNS) disorders, such as depression, attention deficit hyperactivity disorder (ADHD) and Parkinson's disease. The invention further relates to pharmaceutical compositions containing the compounds and compositions of the invention as well as methods of inhibiting reuptake of one or more monoamine, such as such as dopamine and norepinephrine, from the synaptic cleft, and methods of modulating one or more monoamine transporter.
Abstract:
The invention relates to a novel processes for producing ketones, and more specifically, to processes for producing unsaturated ketones using Ca/Na on silica as solid base supported catalysts. This process results in yields and greater selectivity for the target products, while allowing the recycling of the catalyst.